A Microbe Most People Have Never Heard Of, and What It Tells Us About Colon Health
- Joyce Knieff, ND, LAc
- 6 days ago
- 6 min read
Updated: 2 days ago
TL;DR: A new paper found that Methanobrevibacter smithii, a common gut archaeon, shows up more often in people with colorectal cancer and appears to cooperate metabolically with cancer-linked bacteria — but the evidence-supported levers for lowering risk are still fiber, plant diversity, and age-appropriate screening.
Key takeaways:
M. smithii is a normal resident of roughly half to two-thirds of healthy adult guts; presence alone isn't a problem.
The concern is community behavior — how it cross-feeds with Fusobacterium nucleatum, a bacterium already linked to colorectal cancer.
The dietary levers (fiber, plant diversity, fewer ultra-processed foods) still apply.
Microbiome testing is research-grade right now; colonoscopy and stool-based screening remain the diagnostic tools.
For most of the last two decades, when researchers talked about the gut microbiome, they meant bacteria. Trillions of them, certainly, but bacteria all the way down. A new paper out of the Medical University of Graz, published in February 2026 in Nature Communications, asks us to widen the frame. The researchers focused on a different category of microbe altogether, the archaea, which are evolutionarily distinct from both bacteria and human cells. They found that one specific archaeon, Methanobrevibacter smithii, shows up consistently in the guts of people with colorectal cancer, and that it appears to cooperate metabolically with bacteria already linked to the disease.
This is early science. It doesn't mean that M. smithii causes colon cancer or that finding it on a stool test is a diagnosis of anything. What it does suggest is that the conversation about gut health and cancer risk is more layered than the bacteria-only story has allowed.
What the research found
The team, led by microbial ecologist Christine Moissl-Eichinger, pulled together microbiome data from 19 independent clinical studies covering a range of conditions. Their question: do archaea correlate with disease in any consistent way? The answer was largely no, with one exception. Across multiple datasets, M. smithii was reliably enriched in the stool of people diagnosed with colorectal cancer compared to healthy controls.
On its own, that's a correlation. The researchers wanted mechanism, so they built metabolic models of how M. smithii might interact with bacteria already implicated in colorectal cancer, then tested those interactions in lab co-cultures. Two findings stood out. First, M. smithii and Fusobacterium nucleatum, a bacterium that has been linked to colorectal cancer in dozens of studies, appear to support each other's growth and metabolism. Second, when M. smithii and Fusobacterium are grown together, they produce metabolites with tumor-modulating properties, meaning compounds that could plausibly influence the local environment around colon tissue.
The authors are careful with their language. They describe their work as mechanistic insight into how the gut archaeome may participate in colorectal-cancer-associated microbial networks. Their careful framing: the microbial ecosystem around colorectal cancer involves more players than we thought. They stop short of any causal claim.
Where this fits in the wider research
Methanobrevibacter smithii is a normal resident of the human gut. It's the most common methane-producing archaeon there and is found in roughly half to two-thirds of healthy adults, depending on the population studied. In other words, having it is normal. The question this paper raises is how M. smithii behaves in the company of certain bacterial neighbors. Its presence is common; its behavior is what the researchers wanted to characterize.
The broader research literature on diet, the microbiome, and colorectal cancer keeps pointing in similar directions. A 2026 review in Gut Microbes synthesized current evidence on how diet reshapes microbial ecology, modulates microbial virulence, and alters host metabolic and inflammatory pathways relevant to colorectal carcinogenesis. The central pattern across that literature: low-fiber, high-ultra-processed-food, Western-style eating patterns favor mucosal inflammation and a microbial environment that supports tumor-friendly metabolism. Fiber-rich, polyphenol-rich, mostly-plants eating patterns favor short-chain-fatty-acid producers and an environment that pushes in the other direction.
So the new paper doesn't exist in isolation. It adds a kingdom of microbes, the archaea, into a story that already had diet, fiber, inflammation, and bacterial ecology in it.
The naturopathic perspective
Naturopathic practice has talked about the gut as ecosystem for decades, sometimes with more conviction than evidence behind it. The science is finally catching up, and the picture it's painting is more layered than the binary "good bug, bad bug" framing that dominates supplement marketing.
What this paper points at is community behavior. Both microbes here are common residents in many gut microbiomes; neither M. smithii nor Fusobacterium nucleatum is inherently dangerous or always pathogenic on its own. The trouble shows up when certain microbes find each other in certain conditions, when the local environment favors their cross-feeding, and when the host context, including diet, inflammation, motility, and immune tone, is set up in a way that lets that cooperation flourish. That's a systems conversation, which is exactly the kind of clinical reasoning our gut health program is built around.
Practically, this means the levers patients actually have are still the foundational ones. Fiber intake. The diversity and quantity of plants in the diet. Inflammation reduction. Motility. Adequate stomach acid and bile flow. Sleep and stress regulation, which influence the immune-microbiome conversation. None of those interventions promise to prevent cancer. All of them are part of the broader public-health and lifestyle evidence base for lowering colorectal cancer risk over decades, and they happen to be exactly the kinds of interventions that nudge a microbial community toward the healthier end of the spectrum.
Worth saying clearly: any specific concern about colorectal cancer risk belongs in a conversation with your physician and includes age-appropriate screening. Colonoscopy and stool-based screening are still the most evidence-supported tools for catching colorectal cancer early. Microbiome testing belongs in the research category right now; colonoscopy and stool-based screening are still the diagnostic-grade tools.
How to apply this now
A few practical pieces, framed as everyday lifestyle support. Eat plants on purpose: aim for 30 different plant foods a week, including legumes, nuts, seeds, whole grains, and a wide variety of vegetables. That diversity is the single best dietary lever we have for microbial diversity. Lean into fiber, ideally 25 to 35 grams a day from food. Reduce ultra-processed foods, which are the dietary pattern most associated with the inflammatory microbial environment that the new paper situates colorectal cancer within. Take constipation seriously, because transit time matters for colon-mucosa exposure to whatever the microbial community is producing. Move your body daily, since exercise independently shifts the microbiome toward a more anti-inflammatory profile. Stay current with screening. If you have a family history of colon cancer or any persistent change in bowel habits, please don't put off the conversation with your provider.
For anyone managing inflammatory bowel disease, prior colon polyps, or other risk factors, this kind of layered foundational work belongs alongside conventional surveillance, supporting it rather than substituting for it.
Frequently asked questions
Should I get tested for M. smithii?
Not based on this study. M. smithii is a normal inhabitant of roughly half to two-thirds of healthy adult guts, and finding it on a stool test doesn't tell you much on its own. The interesting question — how it behaves in a particular microbial community — isn't something current consumer microbiome tests can answer well. Microbiome testing belongs in the research category for now.
Does this mean I'm at higher risk for colon cancer?
The study shows a correlation, not a cause. Plenty of people carry M. smithii and never develop colorectal cancer. The takeaway isn't to worry about one microbe; it's that the local environment in your colon — shaped by diet, motility, inflammation, and overall microbial diversity — matters. Age-appropriate screening still matters more than any test currently on the consumer market.
How much fiber should I actually be getting?
Most adults benefit from 25 to 35 grams per day, ideally from food rather than supplements. Beans, lentils, whole grains, vegetables, fruit, nuts, and seeds all contribute. A practical target many patients find easier than counting grams: aim for 30 different plant foods per week. That diversity drives microbial diversity in a way that totals alone can't.
What does Yggdrasil recommend for colon and gut health?
A foundational approach — fiber and plant diversity at the center, consistent motility, inflammation reduction, and lifestyle factors like sleep, stress regulation, and movement. For patients with specific concerns (a family history of colon cancer, persistent bowel changes, IBD, polyps), this work belongs alongside, not in place of, conventional surveillance with your physician.
Where does the evidence go from here?
The paper opens a door rather than closing one. Expect more research over the next few years on archaea–bacteria interactions in the colon, on whether targeting these microbial communities can influence cancer risk, and on whether any of this translates into clinically useful testing or treatment. For now, the safest and most evidence-supported moves are the foundational ones.
References
Mohammadzadeh R, Mahnert A, Zurabishvili T, et al. Cross-domain metabolic interactions link Methanobrevibacter smithii to colorectal cancer microbial ecosystems. Nat Commun. 2026;17(1). PMID: 41720792. DOI. Original AANP digest link: https://pubmed.ncbi.nlm.nih.gov/41720792/
Thakur BK, Choudhury SR, Turpin W, Martin A. Gut microbiota and diet in colorectal cancer: Converging determinants of carcinogenesis. Gut Microbes. 2026;18(1):2664684. PMID: 42083308. DOI.
A note before you go
This is for educational purposes and is not a substitute for individualized medical care. Colorectal cancer screening recommendations vary by age, family history, and personal risk factors. Please discuss screening, microbiome testing, and any change in bowel habits with a provider who knows your history.
Related reading
Reviewed by Joyce Knieff, ND, LAc on 2026-05-22.
If this resonates with what you're experiencing and you'd like to explore a naturopathic approach, book a consultation with our clinic.
Comments